AgingResearch.NewsJoin free

Phase 1/2Completed

Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies

A Phase 1b/2 Open-Label, Dose Escalation & Expansion Study of Orally Administered Viracta (VRx)-3996 & Valganciclovir in Subjects With Epstein-Barr Virus-Associated Lymphoid Malignancies

Sponsor
Viracta Therapeutics, Inc. (Industry)
Enrollment
64 enrolled
Conditions
Epstein-Barr Virus-Associated Lymphoma; Lymphoproliferative Disorders
Interventions
VRx-3996 and valganciclovir
Ages
adults, older adults
Registry
NCT03397706

Full record on ClinicalTrials.gov

From the registry

A two part, Phase 1b/2 study to define a recommended Phase 2 dose of VRx-3996 in combination with valganciclovir (Phase 1b) designed to evaluate the efficacy of this combination in relapsed/refractory Epstein-Barr Virus Associated Lymphoma (EBV+ lymphomas).

Primary outcomes

  • Number (Proportion) of Participants With Adverse Events (AEs)
  • Number (Proportion) of Participants With Dose-Limiting Toxicities (DLTs) in Phase 1b
  • Overall Response Rate

History

  1. Results first posted

  2. Last registry update

  3. Study completion

  4. Primary completion

  5. Started

  6. Registered